- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production | 1 | Cision News | ||
| 15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
| 14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News | ||
| 26.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for WorkBeads Worth 2.65 Million SEK | 2 | Cision News | ||
| 21.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes year-end report Q4 2024 | 1 | Cision News | ||
| 14.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies Doubles Production Capacity to Meet Growing Demand | 5 | Cision News | ||
| 10.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a third follow-up order for WorkBeads affimAb worth SEK 4.0 million | 1 | Cision News | ||
| 31.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Follow-Up Order for WorkBeads affimAb Worth 4.6 MSEK | 1 | Cision News | ||
| 14.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Confirms a New Order for WorkBeads affimAb for Use in Antibody Production for 11.2 MSEK | 1 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: The first day to exercise Bio-Works Technologies AB's warrants of series TO 2 is today | 1 | Cision News | ||
| 07.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 1.044 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen | |
| 02.07.24 | Nasdaq Stockholm AB: Delisting of Bio-Works Technologies AB from Nasdaq First North Growth Market | 505 | GlobeNewswire | Bio-Works Technologies AB has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Bio-Works... ► Artikel lesen | |
| 27.06.24 | Nasdaq Stockholm AB: Bio-Works Technologies AB receives observation status | 323 | GlobeNewswire | On June 26, 2024, Bio-Works Technologies AB (the "Company") issued a press
release where the Company announced its intention to change listing from Nasdaq
First North Growth Market to Spotlight Stock... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 14,330 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 41,400 | +1,97 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 11,170 | 0,00 % | Lilly To Acquire Verve Therapeutics For One-Time Cardiovascular Treatments | ||
| DYNE THERAPEUTICS | 10,630 | 0,00 % | H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock | ||
| SUMMIT THERAPEUTICS | 20,940 | 0,00 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 29,060 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,965 | -0,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,215 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| EDGEWISE THERAPEUTICS | 14,750 | +4,02 % | Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | - Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) -
- Strengthened balance sheet with net proceeds... ► Artikel lesen | |
| QUANTUM-SI | 1,880 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,840 | 0,00 % | ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios | ||
| UNICYCIVE THERAPEUTICS | 6,940 | 0,00 % | Unicycive Therapeutics, Inc. - 8-K, Current Report | ||
| AARDVARK THERAPEUTICS | 15,760 | +18,23 % | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions | Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,710 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 6,480 | 0,00 % | TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.